VCYT analyst estimates
Veracyte (VCYT) analyst ratings, the average price target and its range, and every firm's latest call.
VCYT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Veracyte assumed with a Buy at UBS | $65.00 |
| Aug 4, 2026 | Piper Sandler | Veracyte price target lowered to $54 from $66 at Piper Sandler | $54.00 |
| Aug 4, 2026 | Stephens | Veracyte price target lowered to $55 from $68 at Stephens | $55.00 |
| Aug 4, 2026 | Morgan Stanley | Veracyte price target lowered to $44 from $47 at Morgan Stanley | $44.00 |
| Aug 3, 2026 | Canaccord Genuity | Veracyte price target lowered to $50 from $60 at Canaccord | $50.00 |
| Jul 31, 2026 | Needham | Veracyte, Inc (VCYT) PT Raised to $69 at Needham | $69.00 |
| Jul 15, 2026 | Piper Sandler | Veracyte initiated with an Overweight at Piper Sandler | $66.00 |
| Jul 14, 2026 | Canaccord Genuity | Veracyte price target raised to $60 from $42 at Canaccord | $60.00 |
| Jul 9, 2026 | Morgan Stanley | Veracyte price target raised to $47 from $37 at Morgan Stanley | $47.00 |
| Jun 29, 2026 | Guggenheim | Veracyte price target raised to $65 from $45 at Guggenheim | $65.00 |
| Jun 1, 2026 | Needham | Veracyte, Inc (VCYT) PT Raised to $57 at Needham | $57.00 |
| May 6, 2026 | Canaccord Genuity | Veracyte price target raised to $42 from $40 at Canaccord | $42.00 |
| May 6, 2026 | UBS | Veracyte price target raised to $52 from $48 at UBS | $52.00 |
| Mar 5, 2026 | Morgan Stanley | Veracyte, Inc (VCYT) PT Lowered to $37 at Morgan Stanley | $37.00 |
| Jan 5, 2026 | Guggenheim | Veracyte price target raised to $50 from $45 at Guggenheim | $50.00 |
- 9 firms rate VCYT: 7 buy, 1 hold, 1 sell.
- The average price target is $57.43 from 7 analysts, from $44.00 to $69.00.
Updated 2026-11-02 17:13 UTC